NewsBlaze logo
Newsletter logo   Search News     Daily News   
web2.0 logo   win logo
Published:

Diplomat Specialty Pharmacy Tapped by Teva Neuroscience for Therapy Optimization Study for Multiple Sclerosis (TOP MS)

SWARTZ CREEK, Mich., Oct. 10 /PRNewswire/ -- Diplomat Specialty Pharmacy announced today that Teva Neuroscience has selected Diplomat Specialty Pharmacy to be one of only three sites to participate in a large scale, national Therapy Optimization Study for Multiple Sclerosis (TOP MS).

The goal, of the two year TOP MS study, is to examine the benefits of a specialty pharmacy therapy management program on compliance, adherence and patient outcomes. Targeted patient outcomes will include: Relapses, Disability Progression, Quality of Life, and Work and Usual Activity Participation.

"We are honored that Teva Neuroscience selected Diplomat to participate in this study," said Phil Hagerman, President and CEO of Diplomat. "I have no doubt that the TOP MS study will validate the benefits of our patient centric model. When we focus on adherence and tolerance, and offer patients a personalized medication program, we can reduce the frequency and severity of relapses and ultimately improve the quality of life."

"Diplomat Specialty Pharmacy was selected to participate in this study because they have shown a commitment to therapy management in MS that is exemplary among Specialty Pharmacies," said MerriKay Oleen-Burkey, Project Leader for the TOP MS Study at Teva Neuroscience.

"This really is a credit to Diplomat's industry leading MS Navigator program that currently benefits physicians and especially MS patients across the country," said Ken Visser, Diplomat's National Accounts Manager for Multiple Sclerosis. "At Diplomat we maximize therapy adherence by enhancing patient education and prescriber communication. Using our exclusive eNAV(TM) patient care software system, we can electronically record and report our patients' therapy and disease. All of this combined amounts to some of the highest patient adherence numbers in the country."

About Diplomat Specialty Pharmacy

Diplomat Specialty Pharmacy is the nation's largest independently held Specialty Pharmacy and focuses on complete medication management programs for patients with serious and chronic conditions. Key programs include: Oncology, HIV/AIDS, Hepatitis C, Multiple Sclerosis, Rheumatoid Arthritis, Crohn's and Psoriasis. Other specialty areas include Transplant, Fertility, Dialysis Medication Management, Bio-Identical Hormone Replacement Therapy and Specialty Compounding. The company also specializes in Disease Management programs for Chronic Kidney Disease patients, as well as Home and Out-Patient Infusion. With locations inFlint,Swartz Creek andGrand Rapids, MI; Cleveland, OH;Chicago, IL; andFt. Lauderdale, Florida; Diplomat services the specialty pharmacy needs of patients and physicians nationwide.

About Teva Neuroscience

Teva Neuroscience is the branded neurological products franchise of Teva Pharmaceutical Industries Ltd. and is responsible for the development, registration and marketing for Teva's branded neurological products inNorth America. Teva Neuroscience has administrative, commercial marketing, and other leadership functions based inKansas City, MO at its North American headquarters, as well as a facility inHorsham, PA, home to the company's clinical research activities and regulatory functions, and an office in Montreal, Quebec, headquarters for the company's Canadian presence.

    Contact:  Ken Visser, National Accounts Manager for Multiple Sclerosis
    Phone:    616-242-1082
    Fax:      616-454-9095
    Email:    kvisser@diplomatpharmacy.com

SOURCE Diplomat Specialty Pharmacy

Tags: ,MTC,HEA,STW,NET,CPR,TRI,SVY,JVN,MI-Diplomat-Teva-stdy
   _   _

  care2 logo   digg logo   blogger logo   newsfeeder logo   netscape logo  
Is your favorite bookmark site missing? Ask for it.
marker


Sponsor Links:

Writers Wanted
Help NewsBlaze provide daily news, including top stories, Home and Garden, Technology, The Environment and more. NewsBlaze Writer
Relevant Sites:

NewsBlaze 

Copyright © 2004-2008 NewsBlaze LLC
Use of this website is subject to our Terms of Service and Privacy Policy       Support    Press Room